利培酮在痴呆伴或不伴心血管疾病患者中的卒中风险:基于人群的匹配队列研究
该研究基于英国临床实践研究数据链,纳入2004至2023年间65岁后确诊痴呆的个体,比较启用利培酮者与倾向评分匹配对照的1年卒中风险。总体队列中利培酮与卒中风险增加相关(调整后风险比1.28;95%CI 1.20-1.37),且在各心血管疾病和卒中病史亚组中相对风险相似(风险比1.23至1.44)。有心血管疾病史者卒中风险显著升高,利培酮进一步加剧该风险,无心血管疾病史者使用利培酮亦增加卒中风险。
要点
- 痴呆患者使用利培酮与1年卒中风险增加相关,调整后风险比1.28(95%CI 1.20-1.37)。
- 有卒中或心血管疾病史者使用利培酮后卒中发生率更高,相对风险在各亚组相似。
- 无心血管疾病史者使用利培酮仍增加卒中风险,处方时需权衡利弊。
核心结论
- 痴呆患者使用利培酮与卒中风险增加相关,有心血管疾病史者风险更高且利培酮进一步加剧该风险。
- 无心血管疾病史者使用利培酮亦增加卒中风险。
研究设计与样本
- 基于英国临床实践研究数据链的匿名初级保健数据,识别2004至2023年间65岁后确诊痴呆的个体。
- 比较启用利培酮者与倾向评分匹配对照的1年卒中风险,并按卒中及心血管疾病史进行亚组分析。
主要发现
- 利培酮使用者中,有卒中史者卒中发生率为222/1000人年,有心血管疾病史者为94.1/1000人年,总体队列为53.3/1000人年。
- 各心血管疾病和卒中亚组比较中,利培酮相关相对风险相似(风险比1.23至1.44)。
关键数值与推荐
- 利培酮使用者总体卒中调整后风险比1.28(95%CI 1.20-1.37)。
- 有卒中史者卒中发生率222/1000人年,有心血管疾病史者94.1/1000人年,总体53.3/1000人年。
- 各亚组利培酮相关风险比介于1.23至1.44之间。
临床怎么用
- 对痴呆患者处方利培酮前应评估卒中及心血管疾病史,并告知卒中风险增加。
- 有心血管疾病史者卒中风险显著升高,使用利培酮需更谨慎权衡利弊。
- 无心血管疾病史者使用利培酮仍增加卒中风险,应遵循非药物干预优先原则。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Agitation and aggression occur in up to half of people living with dementia over the course of the disease. Although non-pharmacological interventions are used as first-line treatment strategies, antipsychotics may be indicated in severe cases. A major adverse effect of antipsychotics in dementia is stroke; the mechanism of action of atypical antipsychotic risperidone has been linked to cardiovascular disease (CVD) biological pathways in preclinical studies. AIMS: To evaluate the risk of stroke associated with risperidone across different patient subgroups defined by stroke and CVD history. METHOD: Anonymised primary care data from the UK-based Clinical Practice Research Datalink were used to identify individuals diagnosed with dementia after the age of 65 years between 2004 and 2023. Risk of stroke over 1 year was compared between individuals initiating risperidone and propensity-score-matched controls across subgroups with and without history of stroke and any CVD. RESULTS: In the overall cohort (28 403 risperidone users and 136 324 mtatched controls), risperidone was associated with increased risk of stroke (adjusted hazard ratio: 1.28; 95% CI: 1.20-1.37). In the risperidone user group, the incidence rate of stroke was substantially higher in those with a prior history of stroke (incidence rate: 222 per 1000 person-years) and CVD (incidence rate: 94.1 per 1000 person-years) than in the overall cohort (incidence rate: 53.3 per 1000 person-years). Relative risks related to risperidone were similar across all CVD and stroke subgroup comparisons (hazard ratios between 1.23 and 1.44). CONCLUSIONS: People with dementia with a prior history of CVD are at a significant increased risk of stroke, and risperidone further exacerbates this risk. Moreover, risperidone increases risk of stroke in patients without a prior history of CVD. This quantification of stroke risk across subgroups with and without history of CVD may help with communication of risk and aid more judicious prescribing.
引用
- Choma J, Griffiths A, Henley W, et al. Risk of stroke associated with risperidone in dementia with and without comorbid cardiovascular disease: population-based matched cohort study. Br J Psychiatry. 2025. PMID: 41063545. doi:10.1192/bjp.2025.10419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。